New combination treatment for advanced solid tumors
Part of Cancer, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new combination therapy called IBI363 in people with advanced solid tumors, specifically lung cancer with EGFR mutation or ovarian cancer. It aims to see if the drug can shrink tumors and slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need to have advanced or metastatic solid tumors (specifically lung cancer with EGFR mutation or ovarian cancer) that can't be removed by surgery.
- Your previous treatments must have stopped working or caused intolerable side effects.
- You should be physically able to manage daily activities (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- Your blood counts, liver, kidney, and heart function need to be within acceptable limits.
- You must have at least one measurable tumor to track the response.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
This trial tests a new drug called IBI363 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow cancer growth.
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
This trial tests a new drug called IBI3005, given with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It may help shrink tumors or slow their growth.
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
This trial tests a new drug called IBI363 in patients with advanced gastric or gastroesophageal junction cancer who have not yet received any treatment. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
Hear when a new EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.